However, in HGG patients, immune checkpoint inhibitors demonstrated poor efficacy: nivolumab failed to extend survival compared to standard treatment in two phase III trials analyzing newly diagnosed MGMT (O6-Mthylguanine-DNA Methyltrasferase)-methylated and recurrent glioblastoma patients [14]; moreover, pembrolizumab showed poor results in a phase Ib trial compared to bevacizumab, in selected recurrent PD-L1 positive, glioblastoma patients [15]. The gene discussed is MGMT; the disease is glioblastoma.